Clovis Oncology, Inc. (CLVS) News
Filter CLVS News Items
CLVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLVS News Highlights
- CLVS's 30 day story count now stands at 12.
- Over the past 21 days, the trend for CLVS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- ACAD and SE are the most mentioned tickers in articles about CLVS.
Latest CLVS News From Around the Web
Below are the latest news stories about Clovis Oncology Inc that investors may wish to consider to help them evaluate CLVS as an investment opportunity.
Clovis Oncology Inc. (NASDAQ: CLVS) Is A Buzzing Hot StockClovis Oncology Inc. (NASDAQ:CLVS) traded at $4.35 at close of the session on Tuesday, 10/19/21, made an upward move of 3.82% on its previous days price. Looking at the stock we see that its previous close was $4.19 and the beta (5Y monthly) reads 1.65 with the days price range being $4.1699 $4.3799. In Clovis Oncology Inc. (NASDAQ: CLVS) Is A Buzzing Hot Stock Read More » |
$38.38 Million in Sales Expected for Clovis Oncology (NASDAQ:CLVS) This QuarterWall Street brokerages predict that Clovis Oncology (NASDAQ:CLVS) will post $38.38 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Clovis Oncologys earnings, with estimates ranging from $37.30 million to $39.77 million. Clovis Oncology reported sales of $38.77 million in the same quarter last year, which indicates [] |
Expanding Compliance Obligations of the Board Part 2: Clovis OncologyWhen the Delaware Supreme Court says of a Board of Directors collectively signed a companys Annual Statement with hands on their ears to muffle the alarms you can rest assured the Board was seriously negligent in fulfilling its Caremark obligations. The Courts decision in Clovis Oncology (Clovis or the company) laid out what a plaintiff must prove to create liability for a Board under the Caremark Doctrine. Not only must a Board have oversight of a corporate compliance function it must By: Thomas Fox |
Isotope Technologies Munich SE: ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply AgreementITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology''s Targeted Radionuclide Therapy candidate FAP-2286 ITM Isotope Technologies M |
Clovis Oncology, Inc.: Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply AgreementITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology''s Targeted Radionuclide Therapy candidate FAP-2286 Clovis Oncology, Inc. (NAS |
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply AgreementBOULDER, Colo. & MUNICH, October 19, 2021--Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITM’s therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu), EndolucinBeta®, for use in the clinical development of FAP-2286, Clovis’ fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the firs |
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising CompetitionClovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors. |
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286BOULDER, Colo., October 07, 2021--Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286 |
Can These Former Biotech Growth Stocks Regain Their Form?Acadia Pharmaceuticals and Clovis Oncology may be turnaround stories in the making. |
Boulder-based Clovis pays off notes, raises more than $40MIn an effort to clean up its balance sheet, cancer-drug manufacturer Clovis Oncology Inc. (NYSE: CLVS) has paid off $64.4 million in maturing convertible senior notes due in 2021 and raised more than $40 million in new financing through at-the-market offerings. |